Nursing and Health Professions
Chemiluminescence Immunoassay
100%
Castration Resistant Prostate Cancer
100%
Abiraterone
100%
Enzalutamide
100%
Clinical Practice
33%
Clinical Laboratory
33%
Clinical Decision Making
33%
Prostate Cancer
33%
Prostate Specific Antigen
33%
Prevalence
33%
Androgen Receptor
33%
Messenger RNA
33%
Medicine and Dentistry
Circulating Tumor Cell
100%
Castration Resistant Prostate Cancer
100%
Chemiluminescence Immunoassay
100%
Targeted Therapy
60%
Abiraterone
60%
Enzalutamide
60%
Clinical Trial
40%
Prostate Cancer
20%
Androgen Receptor
20%
Prevalence
20%
Clinical Decision Making
20%
Prostate Specific Antigen
20%
Antigen Response
20%
Messenger RNA
20%
Keyphrases
Clinical Utility
100%
Metastatic Castration-resistant Prostate Cancer (mCRPC)
100%
AR-V7
100%
Circulating Tumor Cells
38%
Enzalutamide
23%
Abiraterone
23%
AR-targeted Therapy
23%
Clinical Trials
15%
Taxane Chemotherapy
15%
United States
7%
Androgen Receptor
7%
Improved Outcomes
7%
Castration-resistant Prostate Cancer
7%
Clinical Practice
7%
Canada
7%
Clinical Decision-making
7%
Johns Hopkins University
7%
Splice Variant
7%
Clinical Grade
7%
Prior Exposure
7%
Nave
7%
Messenger RNA Expression
7%
Questionnaire Survey
7%
Change Management
7%
Clinical Laboratory Improvement Amendments
7%
Prostate-specific Antigen Response
7%
Taxane Therapy
7%
Overall Management
7%
Neuroscience
Taxane
100%
Prostate
100%
Enzalutamide
100%
Abiraterone
100%
Clinical Decision Making
33%
Prostate Specific Antigen
33%
Androgen Receptor
33%
Messenger RNA
33%